These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30296805)

  • 1. Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.
    Kutoh E; Hayashi J
    Drug Res (Stuttg); 2019 May; 69(5):297-300. PubMed ID: 30296805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.
    Yang M; Yue H; Xu Q; Shao S; Chen Y
    Diabetes Obes Metab; 2024 Aug; 26(8):3137-3146. PubMed ID: 38699792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
    Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract]   [Full Text] [Related]  

  • 5. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M
    Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus.
    Koike Y; Shirabe SI; Maeda H; Yoshimoto A; Arai K; Kumakura A; Hirao K; Terauchi Y
    Diabetes Res Clin Pract; 2019 Mar; 149():140-146. PubMed ID: 30716347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
    Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
    Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research digest: SGLT2 inhibition in kidney and liver disease.
    Preiss D; Sattar N
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
    [No Abstract]   [Full Text] [Related]  

  • 12. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
    Kutoh E; Wada A; Murayama T; Hayashi J
    Drugs R D; 2018 Dec; 18(4):309-315. PubMed ID: 30324549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia.
    Harris DD; Sabe SA; Xu CM; Sabra M; Broadwin M; Malhotra A; Li JW; Abid MR; Sellke FW
    Surgery; 2024 Feb; 175(2):265-270. PubMed ID: 37940431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
    Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
    Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes: Lower risk of cardiovascular death with canagliflozin.
    Huynh K
    Nat Rev Cardiol; 2017 Aug; 14(8):442. PubMed ID: 28660893
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
    Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.